Skye Bioscience will present a corporate overview at the TD Cowen Health Care Conference on March 5, 2025.
Quiver AI Summary
Skye Bioscience, Inc. has announced that its CEO, Punit Dhillon, will present an overview of the company and participate in one-on-one meetings at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, in Boston. The company is focused on developing innovative treatments for obesity and metabolic disorders, particularly through its Phase 2 clinical trial of nimacimab, an antibody targeting CB1 receptors, which is being studied both as a standalone treatment and in combination with a GLP-1R agonist. Skye aims to create therapeutics with significant clinical and commercial advantages by leveraging biologic targets with proven human mechanisms. A live and archived webcast of the presentation will be available on the company’s website.
Potential Positives
- Skye Bioscience is participating in a significant industry event, the TD Cowen 45th Annual Health Care Conference, which could enhance its visibility among investors and industry stakeholders.
- The CEO, Punit Dhillon, will present a corporate overview and be available for 1x1 meetings, potentially strengthening investor relations and interest in the company's pipeline.
- The company is in the process of conducting a Phase 2 clinical trial for nimacimab, indicating ongoing progress in its research and development efforts in addressing obesity, a major global health issue.
Potential Negatives
- The reliance on forward-looking statements increases uncertainty regarding the company's future performance and could lead to investor skepticism if results do not meet expectations.
- Potential risks and uncertainties related to capital resources and testing outcomes may deter investors and impact stock price negatively.
- The need to disclose significant risks in their filings may indicate existing vulnerabilities in their business strategy and operational stability.
FAQ
What is Skye Bioscience's focus area?
Skye Bioscience focuses on developing new therapeutic pathways for obesity and other metabolic health disorders.
When will Skye present at the TD Cowen Health Care Conference?
Skye will present on March 5, 2025, from 11:10 AM to 11:40 AM ET.
Where will Skye's presentation take place?
The presentation will be held in Boston, MA.
What is nimacimab and its significance?
Nimacimab is a negative allosteric modulating antibody under trial for obesity, inhibiting the CB1 receptor.
How can I access Skye's conference presentation online?
A live and archived webcast of the presentation will be available on Skye's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SKYE Insider Trading Activity
$SKYE insiders have traded $SKYE stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $SKYE stock by insiders over the last 6 months:
- ANDREW J. SCHWAB has made 0 purchases and 6 sales selling 266,337 shares for an estimated $1,750,352.
- PARTNERS VII, LLC 5AM has made 0 purchases and 6 sales selling 266,337 shares for an estimated $1,750,352.
- PAUL A. GRAYSON has made 0 purchases and 2 sales selling 86,551 shares for an estimated $432,061.
- PUNIT DHILLON (Chief Executive Officer) has made 0 purchases and 2 sales selling 82,910 shares for an estimated $413,924.
- KAITLYN ARSENAULT (Chief Financial Officer) has made 0 purchases and 2 sales selling 43,396 shares for an estimated $216,652.
- TUAN TU DIEP (Chief Development Officer) has made 0 purchases and 2 sales selling 19,574 shares for an estimated $97,721.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SKYE Hedge Fund Activity
We have seen 40 institutional investors add shares of $SKYE stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC removed 905,650 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $3,541,091
- BRAIDWELL LP added 825,732 shares (+inf%) to their portfolio in Q4 2024, for an estimated $2,336,821
- PERCEPTIVE ADVISORS LLC removed 500,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,955,000
- SCHONFELD STRATEGIC ADVISORS LLC added 463,644 shares (+48.3%) to their portfolio in Q4 2024, for an estimated $1,312,112
- POINT72 ASSET MANAGEMENT, L.P. removed 416,424 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,178,479
- AWM INVESTMENT COMPANY, INC. removed 400,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,132,000
- MILLENNIUM MANAGEMENT LLC removed 394,386 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,116,112
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN DIEGO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that Punit Dhillon, Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the TD Cowen 45th Annual Health Care Conference.
- Presentation Date: Wednesday, March 5, 2025
- Time: 11:10 AM – 11:40 AM ET
-
Location: Boston, MA
A live and archived webcast will be accessible on Skye’s website .
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( ClinicalTrials.gov: NCT06577090 ) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com . Connect with us on X and LinkedIn .
CONTACTS
Investor Relations
[email protected]
(858) 410-0266
LifeSci Advisors, Mike Moyer
[email protected]
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
[email protected]
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
